T. Rowe Price Associates
ENTA icon

T. Rowe Price Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

T. Rowe Price Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Buy
23,297
+4,593
+25% +$61.7K ﹤0.01% 2802
2026
Q1 		$237K Buy
18,704
+4,294
+30% +$57.6K ﹤0.01% 2774
2025
Q4 		$228K Buy
14,410
+4,264
+42% +$54.2K ﹤0.01% 2766
2025
Q3 		$122K Buy
+10,146
New +$81.1K ﹤0.01% 2892
2023
Q4 		– Sell
-11,678
Closed -$131K – 2910
2023
Q3 		$131K Buy
+11,678
New +$188K ﹤0.01% 2609
2023
Q2 		– Sell
-162,694
Closed -$6.58M – 2905
2023
Q1 		$6.58M Sell
162,694
-11,609
-7% -$554K ﹤0.01% 1124
2022
Q4 		$8.11M Sell
174,303
-66,384
-28% -$3.03M ﹤0.01% 1092
2022
Q3 		$12.5M Buy
240,687
+52,344
+28% +$3.06M ﹤0.01% 1024
2022
Q2 		$8.9M Sell
188,343
-4,716
-2% -$256K ﹤0.01% 1339
2022
Q1 		$13.7M Sell
193,059
-81,258
-30% -$5.29M ﹤0.01% 1321
2021
Q4 		$20.5M Buy
274,317
+12,194
+5% +$957K ﹤0.01% 1282
2021
Q3 		$14.9M Buy
262,123
+9,341
+4% +$462K ﹤0.01% 1365
2021
Q2 		$11.1M Sell
252,782
-611,479
-71% -$29.9M ﹤0.01% 1402
2021
Q1 		$42.6M Sell
864,261
-97,184
-10% -$4.85M ﹤0.01% 1054
2020
Q4 		$40.5M Sell
961,445
-12,984
-1% -$571K ﹤0.01% 1033
2020
Q3 		$44.6M Sell
974,429
-308,128
-24% -$14.9M 0.01% 910
2020
Q2 		$64.4M Sell
1,282,557
-72,381
-5% -$3.75M 0.01% 766
2020
Q1 		$69.7M Sell
1,354,938
-41,397
-3% -$2.21M 0.01% 685
2019
Q4 		$86.3M Sell
1,396,335
-158,917
-10% -$9.85M 0.01% 713
2019
Q3 		$93.4M Buy
1,555,252
+26,711
+2% +$1.98M 0.01% 647
2019
Q2 		$129M Buy
1,528,541
+159,504
+12% +$14.3M 0.02% 581
2019
Q1 		$131M Buy
1,369,037
+295,615
+28% +$26.5M 0.02% 567
2018
Q4 		$76M Buy
1,073,422
+10,338
+1% +$793K 0.01% 679
2018
Q3 		$90.9M Buy
1,063,084
+207,593
+24% +$20.8M 0.01% 701
2018
Q2 		$99.2M Buy
855,491
+537,087
+169% +$53.6M 0.02% 660
2018
Q1 		$25.8M Sell
318,404
-53,606
-14% -$4.13M ﹤0.01% 1096
2017
Q4 		$21.8M Buy
372,010
+269,566
+263% +$13.5M ﹤0.01% 1158
2017
Q3 		$4.79M Buy
+102,444
New +$4.12M ﹤0.01% 1444

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's ENTA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Enanta Pharmaceuticals (ENTA) stake by 25% in Q2 2026, buying an estimated $61.7K and bringing the position to 23,297 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

T. Rowe Price Associates first reported a position in ENTA in Q3 2017 and has held it in 28 quarters since. The position peaked at $131M in Q1 2019. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • T. Rowe Price Associates held 23,297 shares of Enanta Pharmaceuticals worth $340K as of Q2 2026.
  • T. Rowe Price Associates bought 4,593 Enanta Pharmaceuticals shares in Q2 2026, an estimated $61.7K.
  • Enanta Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2802 holding.
  • T. Rowe Price Associates first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Enanta Pharmaceuticals position peaked at $131M in Q1 2019.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.